02/06/2026
BREAKING: First Peer-Reviewed Protocol for Ivermectin, Mebendazole & Fenbendazole in Cancer – Published Sept 19, 2024!
The landmark paper "Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol" (Journal of Orthomolecular Medicine) proposes this combo as a targeted strategy against cancer's energy pathways and stem cells.
Key points from the protocol:
Ivermectin: Induces apoptosis/autophagy, inhibits proliferation, targets CSCs/metastases.
Mebendazole/Fenbendazole: Disrupt microtubules, block glucose uptake, reactivate p53, hit resistant cells.
Synergy with orthomolecular support (e.g., diet, supplements) for low-toxicity approach.
Ivermectin vs. Turbo Cancers & Chemo Resistance:
Preclinical data shows Ivermectin overcomes resistance (e.g., in breast cancer models, outperforms paclitaxel on CSCs; reverses MDR via pathways like EGFR/ERK/Akt/NF-κB). Claims link to mRNA vaccines remain unproven/no large human evidence.
Breast Cancer & Mammography Claims:
Overdiagnosis/false positives are real concerns (10-50%+ in some estimates, higher in older women; cumulative false-positive risk 50-60% over 10 years annual screening). But no credible study shows mammography "stimulates tumor growth/metastases" or causes cancer in 690,000 healthy women – that's misinformation. Benefits (early detection, reduced mortality) outweigh low radiation risks per major guidelines (NCI,
USPSTF).
No treatment claims – research & consult pros.
Pure, high-quality Ivermectin, Fenbendazole, Mebendazole at parasiteheal.com – lab-tested, discreet worldwide shipping.
Thoughts on repurposed protocols? Share below!
